CardIQ Suite vs Tempus ECG-AF

CardIQ Suite emphasizes an integrated workflow for seamless review of cardiac CT data, including automated features like calcium scoring and coronary artery labeling, which suggests a focus on user efficiency and ease of use. Tempus ECG-AF, while providing valuable risk assessment, does not have a dedicated user interface and integrates with other medical systems, which might imply a less direct user experience for clinicians interacting with the AI output.

Tempus ECG-AF is an FDA-cleared AI algorithm specifically designed to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter within 12 months, addressing a critical need for early detection of a common and serious condition. CardIQ Suite offers comprehensive cardiac CT post-processing for diagnosis and treatment planning, but Tempus ECG-AF's predictive capability for a specific, high-impact condition demonstrates a distinct clinical advantage in proactive patient management.

Tempus ECG-AF has a clear advantage in pricing transparency and value due to the availability of CMS reimbursement (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). CardIQ Suite's pricing is listed as 'contact for pricing,' offering no immediate transparency on cost or potential reimbursement pathways.

Both tools demonstrate enterprise readiness through HIPAA compliance and FDA clearance, indicating adherence to critical regulatory and data security standards for healthcare environments. CardIQ Suite is deployed on-premise with GE Advantage Workstation, while Tempus ECG-AF is a software solution integrated into healthcare facility systems, both suggesting robust deployment strategies for enterprise use. Both companies also offer BAA agreements, further solidifying their enterprise readiness.

Both tools showcase innovation in their respective domains. CardIQ Suite leverages deep learning for automated calcium scoring and CCTA review, enhancing cardiac CT post-processing. Tempus ECG-AF utilizes an AI-based algorithm to predict the 12-month risk of atrial fibrillation from 12-lead ECGs, representing a novel application of AI for proactive risk identification.

Both GE Medical Systems SCS (for CardIQ Suite) and Tempus AI, Inc. (for Tempus ECG-AF) are established companies in the healthcare technology space, implying a certain level of support and documentation. GE Healthcare provides access to technical service documents and a customer documentation portal. Tempus AI offers customer service via phone and email, and provides a policy center and document library. Without more specific details on the breadth and accessibility of support and documentation for each specific product, it is difficult to definitively choose a winner.